Antibiotic use, microbiota alterations, and the risk of obesity.

Shota Takeda*

Department of Urology, Osaka University, Japan

Introduction

Antibiotic use has been a cornerstone of modern medicine, effectively treating bacterial infections and saving countless lives. However, the implications of antibiotic therapy extend beyond their intended effects, particularly concerning the human microbiota [1]. The gut microbiota, a diverse community of microorganisms residing in the gastrointestinal tract, plays a vital role in numerous physiological processes, including digestion, immune function, and metabolic regulation. Recent research has illuminated the intricate relationship between antibiotic use, alterations in gut microbiota, and the increasing risk of obesity [2].

Antibiotics can significantly disrupt the balance of gut microbiota. They often kill both pathogenic and beneficial bacteria, leading to dysbiosis—a condition characterized by an imbalance in microbial composition [3]. Dysbiosis has been linked to a variety of health issues, including obesity. Studies have shown that individuals who have undergone multiple courses of antibiotics are at a greater risk of developing obesity later in life. This phenomenon is particularly concerning given the rising prevalence of obesity globally [4].

One of the ways in which antibiotics contribute to obesity is by altering the metabolic pathways of the gut microbiota. Beneficial gut bacteria are involved in the fermentation of dietary fibers and the production of short-chain fatty acids (SCFAs), which play a critical role in regulating energy balance, appetite, and fat storage [5]. When antibiotics disrupt these microbial populations, the production of SCFAs is diminished, potentially leading to increased fat accumulation and changes in energy metabolism. Furthermore, dysbiosis may impair the gut's ability to extract energy from food effectively, resulting in excess calories being stored as fat rather than being used for energy [6].

The timing and duration of antibiotic exposure also play crucial roles in determining its impact on gut health and obesity risk. Early-life exposure to antibiotics, particularly during critical developmental windows, can have lasting effects on the microbiota [7]. Infants who receive antibiotics may experience long-term alterations in their gut microbiota composition, predisposing them to obesity and metabolic disorders later in life. This raises important questions about the use of antibiotics in pediatric populations and the need for more judicious prescribing practices [8].

Emerging research has also explored the potential for gut microbiota restoration through probiotics and prebiotics as a means of mitigating the negative effects of antibiotic-induced dysbiosis [9]. Probiotics, which are live beneficial bacteria, and prebiotics, which are compounds that nourish these bacteria, may help restore a healthy microbial balance and counteract some of the metabolic disturbances associated with antibiotic use. However, more extensive clinical studies are needed to confirm the efficacy of these interventions in preventing obesity [10].

Conclusion

While antibiotics are essential tools for treating infections, their unintended consequences on gut microbiota and the subsequent risk of obesity cannot be overlooked. The disruption of beneficial bacteria can lead to metabolic changes that promote weight gain and obesity. As the understanding of the microbiome's role in health continues to evolve, there is a pressing need for more research into the long-term effects of antibiotic use and strategies to mitigate its impact on gut health.

References

1. Lee P, Yacyshyn BR, Yacyshyn MB. Gut microbiota and obesity: An opportunity to alter obesity through faecal microbiota transplant (FMT). Diabetes Obes Metab. 2019;21(3):479-90.
2. Yallapragada SG, Nash CB, Robinson DT. Early-life exposure to antibiotics, alterations in the intestinal microbiome, and risk of metabolic disease in children and adults. Pediatr Ann. 2015;44(11):265-9.
3. Principi N, Esposito S. Antibiotic administration and the development of obesity in children. Int J Antimicrob Agents. 2016;47(3):171-7.
4. Cornejo-Pareja I, Munoz-Garach A, Clemente-Postigo M, et al. Importance of gut microbiota in obesity. Eur J Clin Nutr. 2019;72(1):26-37.
5. Lange K, Buerger M, Stallmach A, et al. Effects of antibiotics on gut microbiota. Dig Dis. 2016;34(3):260-8.
6. Murphy EF, Cotter PD, Hogan A, et al. Divergent metabolic outcomes arising from targeted manipulation of the gut microbiota in diet-induced obesity. Gut. 2013;62(2):220-6.

***Correspondence to:** Shota Takeda, Department of Urology, Osaka University, Japan. E-mail: takeda@ou.jp.in

Received*:** 24-Aug-2024, Manuscript No. JGDD-24-148640; ***Editor assigned: 26-Aug-2024, Pre QC No. JGDD-24-148640(PQ); ***Reviewed*:** 09-Sep-2024, QC No. JGDD-24-148640; ***Revised:*** 14-Sep-2024, Manuscript No. JGDD-24-148640(R); ***Published:*** 21-Sep-2024, DOI: 10.35841/jgdd-9.5.229

Citation: *Takeda S. Antibiotic Use, Microbiota Alterations, and the Risk of Obesity. J Gastroenterol Dig Dis.2024;9(5):229*

7. Stark CM, Susi A, Emerick J, et al. Antibiotic and acid-suppression medications during early childhood are associated with obesity. Gut. 2019;68(1):62-9.

8. Scott FI, Mamtani R. Antibiotics and obesity—a burgeoning or thinning argument?. JAMA Pediatr. 2017;171(2):118-20.

9. Miller SA, Wu RK, Oremus M. The association between antibiotic use in infancy and childhood overweight or obesity: a systematic review and meta-analysis. Obes Rev. 2018;19(11):1463-75.

10. Moran-Ramos S, López-Contreras BE, Canizales-Quinteros S. Gut microbiota in obesity and metabolic abnormalities: a matter of composition or functionality?. Arch Med Res. 2017;48(8):735-53.

Citation: *Takeda S. Antibiotic Use, Microbiota Alterations, and the Risk of Obesity. J Gastroenterol Dig Dis.2024;9(5):229*